Tech Company Financing Transactions
Eureka Therapeutics Funding Round
Eureka Therapeutics, operating out of Emeryville, secured $60 million in funding from Acorn Pacific Ventures and GP Capital.
Transaction Overview
Company Name
Announced On
1/23/2018
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series D
Investors
Proceeds Purpose
This financing will help expand our drug development efforts, and we look forward to applying our ARTEMIS technology to broader classes of patients than currently can be treated with CAR-T therapies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 170
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Website
Email Address
Overview
Eureka Therapeutics is focused on developing novel T cell immunotherapies for the treatment of solid tumors. Our unique platform is powered by TCR-like antibodies which recognize previously inaccessible cancer antigens specific for solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cheng Liu
Chief Operating Officer
Vivien Chan
VP - Bus. Development
Hanzhong Li
VP - General Counsel
Victor Shum
Browse more venture capital transactions:
Prev: 1/23/2018: Cabify venture capital transaction
Next: 1/23/2018: Hippo venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs